Regenerative technology and stem cell use has been a rapidly increasing field of healthcare, and with new developments and discoveries arising everyday, the United States may experience a breakthrough in these treatments. DG Medical Group, a medical product distributor based out of Clearwater, Florida, has recently obtained a Biologic Drug Master File for it’s Mesenchymal Stem Cell (MSC) Exosomes. This groundbreaking achievement has also earned DG the 100% master distribution contract for exosome products to date.
Collaborating with the first biologics laboratory in the United States with a regulatory compliant Masterfile for MSC exosomes, DG Medical Group provides patients, physicians and clinicians the most advanced and beneficial technology in regenerative medicine. They hope to revolutionize healthcare by leveraging the potential of MSC exosomes, and through interdisciplinary collaboration, research and ethical innovation, their therapies will help to rejuvenate damaged tissues, restore organ function, and provide long-term solutions for patients with debilitating conditions.
“Studies have shown that treatments with exosomes show similar or better results when it comes to enhancing the body’s natural healing processes,” says President, Michael Major. “This is as compared to stem cell treatment. Based on the similar or better results shown with exosomes, it is thought that stem cell treatments achieve beneficial effects through the secretion of exosomes. After all the trials and testing, it’s an amazing scientific advancement that we’re looking forward to developing even further.”
Offering consistency, quality, and regulated products, DG Medical Group aims to provide healthcare workers with trusted products that align with valid, competent concentrations. They partner with local medical research institutions to perform innovative research on the regenerative properties of stem cell derived exosomes. Together with their researchers, they have begun to lay the foundations for the development of FDA-approved clinical exosome products.
“Our mission is to revolutionize healthcare,” says Major. “The research we do in collaboration with other medical research institutions has allowed us to leverage the current solutions we know of and build upon them. Mesenchymal stem cells (MSCs) are multipotent cell types, such as bone cells, cartilage cells, fat cells and muscle cells. Human umbilical cord MSCs are also a type of stem cell that possess immunomodulatory properties. This means that, among other things, they can regulate the immune response. We hope that, with these groundbreaking discoveries and research, that we can continue to improve quality of life, extend healthy lifespans, and contribute to a future where regenerative medicine is a cornerstone of healthcare.”
Regulatory authorities such as the FDA continue to play an important role in ensuring the safety and efficacy of exosome-based therapies, especially as this emerging field of technology increases across the United States. The FDA has recently notified the industry that all regenerative medicine products intended for clinical use must go through their regulatory process. With the research and technology being improved upon as time goes on, DG Medical Group continues to lay the foundation for the development of FDA-approved clinical exosome products. With their official Biologic Drug Masterfile, DG hopes to continue acting as a trailblazer in the world of advanced regenerative healthcare. For more information regarding their research and products, visit the DG Medical Group website.
